<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathogenesis of AA amyloidosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathogenesis of AA amyloidosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathogenesis of AA amyloidosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter D Gorevic, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Helen J Lachmann, MA, MB, BChir, MD, FRCP, FRCPath, FMedSci</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 04, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>AA amyloid results from the deposition in tissue of serum amyloid A (SAA) protein, which is a major acute phase reactant. Amyloidosis encompasses a group of diseases caused by misfolding and extracellular accumulation of proteins as fibrillar deposits [<a href="#rid1">1,2</a>]. These fibrils stain with Congo red and produce pathognomonic green birefringence when viewed by microscopy under crossed polarized light. The process of amyloid formation and deposition causes tissue toxicity and progressive organ dysfunction.</p><p>The pathogenesis of AA amyloidosis is presented here. The clinical manifestations, diagnosis, and treatment of this disorder, an overview of amyloidosis, and the pathogenesis of other forms of amyloidosis are discussed separately. (See  <a class="medical medical_review" href="/d/html/5602.html" rel="external">"Causes and diagnosis of AA amyloidosis and relation to rheumatic diseases"</a> and  <a class="medical medical_review" href="/d/html/5588.html" rel="external">"Treatment of AA (secondary) amyloidosis"</a> and  <a class="medical medical_review" href="/d/html/5589.html" rel="external">"Overview of amyloidosis"</a>.)</p><p class="headingAnchor" id="H2391684817"><span class="h1">AMYLOID PRECURSORS AND AMYLOIDOGENESIS</span><span class="headingEndMark"> — </span>All forms of amyloidosis, including AA amyloidosis, are characterized by codeposition of other molecules, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum amyloid P component (SAP), a member of the pentraxin family that includes C-reactive protein [<a href="#rid2">2</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Glycosaminoglycans, notably heparan sulfate [<a href="#rid3">3</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Apolipoproteins (E and A4) [<a href="#rid4">4</a>]</p><p></p><p>There are 36 different human precursor proteins known to be deposited in a fibrillar configuration as amyloid, 14 associated with systemic disease [<a href="#rid5">5</a>]. Common examples include:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum amyloid A (SAA) protein in AA amyloidosis</p><p class="bulletIndent1"><span class="glyph">●</span>Monoclonal immunoglobulin light chains in primary or immunoglobulin light chain (AL) amyloidosis (see  <a class="medical medical_review" href="/d/html/6665.html" rel="external">"Monoclonal immunoglobulin deposition disease"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Beta-2 microglobulin in dialysis-related amyloidosis (see  <a class="medical medical_review" href="/d/html/1983.html" rel="external">"Dialysis-related amyloidosis"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Transthyretin in wild-type transthyretin (TTR) amyloidosis (previously known as senile cardiac amyloidosis)</p><p class="bulletIndent1"><span class="glyph">●</span>Several different apolipoproteins among the hereditary amyloidoses (see  <a class="medical medical_review" href="/d/html/5590.html" rel="external">"Genetic factors in the amyloid diseases"</a>)</p><p></p><p>A number of factors have been identified that contribute to the pathogenesis of AA amyloid:</p><p class="bulletIndent1"><span class="glyph">●</span>Sustained increase in the serum concentration of SAA in chronic inflammatory states [<a href="#rid6">6</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Post-translational modifications that may influence synthesis or destabilize SAA and favor its misfolding and aggregation [<a href="#rid7">7</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Interruption of ligand binding to various receptors as a result of proteolysis at position 76 of SAA [<a href="#rid8">8</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>The intrinsic propensity of SAA subsequences to misfolding [<a href="#rid9">9</a>]</p><p></p><p>A combination of these factors may determine the amyloidogenicity. Nonetheless, undetermined environmental and genetic factors must also be involved as only a minority of patients with sustained inflammation and persistent elevation of SAA levels develop AA amyloidosis [<a href="#rid2">2</a>].</p><p>Cofactors, such as glycosaminoglycans and SAP, may play a role in predisposition to amyloid formation via one or more of the following effects [<a href="#rid10">10-14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Modulation of fibrillogenesis by direct binding to specific domains of subunit proteins or their precursors</p><p class="bulletIndent1"><span class="glyph">●</span>Stabilization of the fibril and protection from degradation</p><p class="bulletIndent1"><span class="glyph">●</span>Localization to specific organs or tissue sites by binding to matrix components or receptor molecules</p><p class="bulletIndent1"><span class="glyph">●</span>Secondary effects on the metabolism of precursor protein, leading to the accumulation of degradation products with amyloidogenic potential</p><p class="bulletIndent1"><span class="glyph">●</span>Modulation of proteolytic events that may facilitate fibril formation</p><p></p><p class="headingAnchor" id="H2"><span class="h1">SERUM AMYLOID A PROTEIN</span><span class="headingEndMark"> — </span>AA amyloid results from the deposition in tissue of serum amyloid A (SAA) protein, which is a major acute phase reactant [<a href="#rid7">7,15</a>]. (See  <a class="medical medical_review" href="/d/html/7483.html" rel="external">"Acute phase reactants"</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Types</span><span class="headingEndMark"> — </span>Several forms of SAA have been identified in serum. These include acute phase (SAA1 and SAA2) and constitutive (SAA4) isoforms, allelic variants, and post-translational modifications of these gene products [<a href="#rid1">1,7,15</a>]. Acute phase SAA proteins (SAA1 and SAA2) are apolipoproteins, primarily associated with high-density lipoprotein (HDL), and are also expressed extrahepatically (eg, synovial membrane) in the absence of HDL [<a href="#rid16">16</a>]. However, during the inflammatory response, SAA may exchange with low-density lipoproteins [<a href="#rid17">17</a>], and a small fraction binds to retinol-binding protein and indirectly to transthyretin [<a href="#rid18">18</a>].</p><p>Expression of SAA1 and SAA2 is induced by a number of factors, particularly interleukin (IL) 6, but also IL-1, tumor necrosis factor (TNF), lipopolysaccharide (LPS), and several transcription factors (pERK1/2, pjNK, p38), notably including SAA-activating factor (SAF)-1 [<a href="#rid19">19-21</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>SAA1 is the precursor protein in most individuals with AA amyloid [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Binding of heparin to SAA1 displaces it from HDL, perhaps contributing to the mechanism by which heparin and heparan sulfate facilitate formation of AA amyloid [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>SAA1 has three alleles, designated SAA1.1, SAA1.3, and SAA1.5, defined by amino acid substitutions at positions 52 and 57 of the molecule [<a href="#rid23">23</a>]. SAA2 has two alleles (alpha and beta) that differ from each other by a single base pair substitution at codon 71 resulting in an adenine substitution of guanine [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The frequency of these alleles varies between populations and homozygosity for SAA1. SAA1 has been associated with an increased risk of AA amyloidosis in diseases such as rheumatoid arthritis and familial Mediterranean fever in White individuals, perhaps because of increased susceptibility to proteolytic cleavage by specific metalloproteinases [<a href="#rid25">25,26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the Japanese population, specific single nucleotide polymorphisms (SNPs) of the gene for SAA1.3 have been associated with increased gene transcription, AA amyloidosis complicating rheumatoid arthritis, adult-onset Still's disease, and susceptibility to familial Mediterranean fever [<a href="#rid27">27,28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The carrier frequency for <em>MEFV</em> variants and familial Mediterranean fever in Armenia ranges up to one in three persons; Armenian patients homozygous for SAA1-alpha have a sevenfold higher risk of developing renal AA amyloidosis [<a href="#rid29">29</a>].</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Possible function</span><span class="headingEndMark"> — </span>The acute phase response, as reflected in the <em>SAA</em> gene, has been conserved for half a billion years throughout vertebrate evolution. Whereas SAA1 and SAA2 genes are found in most mammalian species due to conversion/duplication of an ancestral gene, fowl and fish have only a single acute phase response SAA, yet some species (eg, Pekin duck, some dolphins) are still susceptible to developing AA amyloid [<a href="#rid21">21</a>]. In humans, SAA is one of the most dynamic components with a potential increase in circulating concentration of more than 1000-fold, implying that it has important functions in the inflammatory response. Nonetheless, the exact contributions SAA proteins play in host defense remain somewhat opaque [<a href="#rid7">7</a>].</p><p>SAA proteins may increase the affinity of HDLs for macrophages and adipocytes during the acute phase response, a property termed "reverse cholesterol metabolism" [<a href="#rid15">15,30,31</a>]. Other properties include extracellular matrix binding [<a href="#rid32">32</a>]; opsonization of Gram-negative bacteria [<a href="#rid33">33</a>]; chemoattractant activity for monocytes, neutrophils, and lymphocytes [<a href="#rid34">34</a>]; induction of the release of proinflammatory cytokines from neutrophils [<a href="#rid35">35,36</a>]; and platelet effects [<a href="#rid37">37,38</a>]. Pro- and antiinflammatory effects of SAA vary with regard to the blood pool of hepatically derived acute phase SAA; local effects of tissue- and macrophage-derived SAA; the use of recombinant SAA for many in vitro studies; and whether SAA is bound to HDL or delipidated [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Ligands</span><span class="headingEndMark"> — </span>SAA interacts specifically with a wide range of ligands, either bound to the surface of HDLs or in a lipid-free form [<a href="#rid40">40</a>]. The former include cholesterol (residues 1 to 18 and 40 to 63 of SAA), HDL (residues 1 to 18), calcium (residues 48 to 51), laminin (residues 29 to 33), fibronectin (residues 39 to 41), cystatin c (residues 86 to 104), and heparin/heparan sulfate (two binding sites within residues 17 to 49 and 77 to 103) [<a href="#rid21">21</a>]; the last ligand, in particular, has been targeted for the development of therapeutic agents for the treatment of AA amyloid [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/d/html/5588.html" rel="external">"Treatment of AA (secondary) amyloidosis"</a>.)</p><p>Some SAA binding may occur selectively within the joint space of patients with rheumatoid arthritis, as both acute phase and constitutive isoforms of SAA appear to be synthesized by synovial tissue [<a href="#rid16">16,42</a>]. High levels of both SAA and its receptor, formyl peptide receptor-like 1 (FPRL1), have been demonstrated in the rheumatoid synovium, and a link to leukocyte infiltration, including the influx of CCR6-expressing Th17 cells, was confirmed by the ability of SAA to upregulate CCR20 expression of rheumatoid arthritis synoviocytes [<a href="#rid43">43</a>]. Acute phase SAA may directly stimulate the production of TNF-alpha and acute phase pentraxin production by synoviocytes [<a href="#rid44">44</a>]; SAA can mediate inflammatory and angiogenic effects by interaction with toll-like receptors (TLR2 and TLR4) [<a href="#rid39">39,45</a>]. Inhibition of IL-6-mediated induction of acute phase SAA in rheumatoid synovium by JAK/STAT (Janus kinase/signal transducer and activator of transcription) inhibitors being developed for clinical use provides another mechanism for abrogating SAA that may have potential for use in inflammatory arthritis, as well as in AA amyloidosis [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H6"><span class="h1">PATHOGENESIS OF AA AMYLOIDOSIS</span><span class="headingEndMark"> — </span>Common causes of AA amyloidosis are rheumatoid arthritis, chronic infections (particularly in resource-limited countries), and autoinflammatory disorders [<a href="#rid47">47,48</a>]. (See  <a class="medical medical_review" href="/d/html/5602.html" rel="external">"Causes and diagnosis of AA amyloidosis and relation to rheumatic diseases"</a>.)</p><p>AA amyloid occurs in various mammalian and avian species and can be induced by chronic inflammatory stimuli. The best-studied model for this disease is amyloid induction by casein/azocasein injections in certain genetically susceptible strains of mice [<a href="#rid49">49</a>]. Although most animal models for AA amyloid parallel human disease with predominant fibril deposition in spleen, liver, and kidney, chickens develop a unique articular amyloidosis when injected with <em>Enterococcus faecalis</em> [<a href="#rid50">50,51</a>]. Transmissibility of systemic AA amyloidosis by a seeding-nucleation process (so-called amyloid-enhancing factor [AEF]) has been identified in the pathogenesis of bovine, avian, mouse, and cheetah AA amyloid [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Principal pathogenic factors</span><span class="headingEndMark"> — </span>Based upon findings in these animal models and results in patients, the principal pathogenic factors in AA amyloidosis (<a class="graphic graphic_figure graphicRef116202" href="/d/graphic/116202.html" rel="external">figure 1</a>) appear to be the following [<a href="#rid1">1,53,54</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Overproduction of both high-density lipoprotein (HDL)-associated and lipid-free serum amyloid A (SAA) as a consequence of acute and chronic inflammation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Proteolytic processing of SAA to AA, with a major cleavage occurring at position 76, thereby releasing the carboxyterminal third of the molecule [<a href="#rid55">55</a>]. The in vitro demonstration of internalization of SAA by macrophages, followed by intracellular proteolysis, and later by release of amyloidogenic peptides into the extracellular space [<a href="#rid56">56</a>], suggests that these events precede fibril formation. However, there is still uncertainty about the order of events in vivo [<a href="#rid12">12,13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Focus on the intralysosomal pathway and acidification as promoting SAA aggregation has provided evidence for oligomers and other prefibrillar soluble aggregates of SAA as contributing to disease pathogenesis, toxicity, and the potential value of therapies that can inhibit aggregation and clear oligomers [<a href="#rid57">57,58</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intrinsic fibrillogenic properties of SAA subsequences, particularly involving the amino-terminal end of the molecule [<a href="#rid59">59,60</a>].</p><p></p><p class="headingAnchor" id="H8"><span class="h3">Increased synthesis</span><span class="headingEndMark"> — </span>There is increased synthesis of SAA with inflammation due to elevated levels of proinflammatory cytokines. With rheumatoid arthritis, for example, this increase in cytokine levels correlates with synovitis, which, in turn, may stimulate synoviocytes to produce SAA [<a href="#rid16">16,34,42,61</a>]. These events lead to elevated levels in joint fluid relative to serum [<a href="#rid42">42</a>]. In addition, SAA may directly potentiate rheumatoid inflammation via the induction of matrix metalloproteinases (MMP1 and MMP3) by synovial cells and chondrocytes [<a href="#rid42">42,44,62</a>].</p><p>Although most acute phase response SAA originates in the liver, SAA1/2 may also be produced by macrophages, kidney, lung, adipocytes, mammary glands, synovial cells, and intestinal epithelial cells (IECs) (<a class="graphic graphic_figure graphicRef116202" href="/d/graphic/116202.html" rel="external">figure 1</a>). Early studies demonstrated SAA to be a major adipokine [<a href="#rid63">63</a>], relevant to the lipoprotein redistribution in obesity [<a href="#rid64">64</a>], inflammation [<a href="#rid24">24</a>], and in some instances, the development of AA amyloidosis [<a href="#rid65">65</a>]. Studies of SAA upregulation in mice and zebrafish, and the development of double and triple SAA knockout mice, have focused attention on possible roles in regulating inflammation and facilitating autoimmunity in inflammatory bowel disease (IBD). In mice, acute phase response SAA production by IECs may be induced by intra-ileal colonization by specific segmented filamentous microbes, triggered by interleukin (IL) 22-producing type 3 innate lymphoid cells, with SAA in turn promoting T helper (Th) 17 differentiation and increased IL-17 produced by these Th cells. This scenario provides a mechanism for SAA modulation of the inflammasome response in IBD, as well as autoimmune disease systemically [<a href="#rid66">66-70</a>].</p><p>The importance of increased SAA synthesis has been demonstrated by the correlation between the serum SAA concentration and disease course in patients with established AA amyloidosis. This was illustrated in a report of 80 patients with AA amyloid (mostly due to juvenile idiopathic arthritis or to rheumatoid arthritis) who were prospectively followed for a median of four years; the systemic amyloid load was assessed by yearly serum amyloid P component (SAP) scintigraphy [<a href="#rid71">71</a>]. The following findings were noted (see  <a class="medical medical_review" href="/d/html/5588.html" rel="external">"Treatment of AA (secondary) amyloidosis"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Forty-two patients had median serum SAA concentration within the reference range (&lt;10 mg/L); amyloid deposits regressed in 25 and stabilized in 14. Among patients with renal disease at baseline, proteinuria typically fell while the serum creatinine concentration was either stable or improved. Two patients who required dialysis remained on dialysis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The outcomes were variable in the other patients. However, among those in whom the serum SAA was persistently above 50 mg/L, the amyloid load usually increased and organ function deteriorated. In one patient who underwent renal transplantation, proteinuria and renal amyloid deposits recurred within 36 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Amyloid deposition increased rapidly in patients with relapse of the underlying inflammatory disease. This observation is consistent with an underlying susceptibility to amyloidosis.</p><p></p><p class="headingAnchor" id="H9"><span class="h3">Processing</span><span class="headingEndMark"> — </span>All forms of AA amyloidosis are associated with increased levels of SAA in blood [<a href="#rid72">72</a>]. In rheumatoid arthritis, however, SAA levels are increased in patients both with and without amyloidosis [<a href="#rid73">73</a>]. This indicates that additional factors (perhaps genetic and environmental) must be involved in pathogenesis [<a href="#rid74">74,75</a>], a feature of pathogenesis underscored by the variable incidence of AA amyloidosis complicating hereditary autoinflammatory disorders [<a href="#rid76">76</a>]. Other factors potentially include aberrant degradation of SAA to AA protein [<a href="#rid77">77</a>] and the accumulation of proteolytic cleavage products attributable to specific enzymes (eg, MMP1) in blood and/or tissue [<a href="#rid78">78</a>].</p><p class="headingAnchor" id="H10"><span class="h3">Intrinsic properties</span><span class="headingEndMark"> — </span>The type and size of the fragments that are formed may also determine both the amyloidogenic potential and the site of tissue deposition [<a href="#rid79">79,80</a>]. Biochemical analysis has shown that smaller fragments are more likely to deposit in the glomeruli, while larger fragments may preferentially deposit in the blood vessels [<a href="#rid80">80</a>]. Cryogenic electron microscopy (CryoEM) studies of AA amyloid fibrils purified from tissue compared with those formed from recombinant peptides suggest that proteolytic selection may be responsible for the dominance of morphologies more likely to damage tissue [<a href="#rid81">81</a>].</p><p class="headingAnchor" id="H11"><span class="h3">Accelerated deposition</span><span class="headingEndMark"> — </span>In murine models of amyloidosis, the deposition phase of disease can be greatly accelerated by injection of AEF, an activity that is probably due to the AA fibrils, peptides, and oligomers that provide a template for amyloid deposition and that is transmissible between animals [<a href="#rid1">1,52,82,83</a>]. The relevance of these observations to the role of SAA in inflammation and the induction of AA amyloid in susceptible individuals with inflammatory diseases remains to be determined [<a href="#rid52">52,84</a>].</p><p class="headingAnchor" id="H10817717"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Amyloidosis is a general term that refers to the predominantly extracellular tissue deposition of fibrils composed of low molecular weight subunits (5 to 25 kD) derived from any of more than 30 diverse serum proteins; these proteins have little in common with regard to their primary structure or metabolism. The fibrils have a predominantly antiparallel beta-pleated sheet configuration; they can be identified on biopsy specimens by tinctorial properties that result from the binding of specific dyes, such as Congo red. All forms of amyloidosis are characterized by codeposition of other substances, and cofactors may play a role in amyloid formation. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic AA amyloid results from the deposition in tissue of serum amyloid A (SAA) protein, which is a major acute phase reactant. SAA proteins may function to increase the affinity of high-density lipoproteins (HDLs) for macrophages and adipocytes during the acute phase response. SAA binds specifically to several ligands, including cholesterol, HDL, calcium, laminin, and heparin/heparan sulfate. (See <a class="local">'Serum amyloid A protein'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Common causes of AA amyloidosis are rheumatoid arthritis, chronic infections (particularly in underdeveloped countries), and autoinflammatory disorders. (See <a class="local">'Pathogenesis of AA amyloidosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The principal pathogenic factors in AA amyloidosis include overproduction of both HDL-associated and lipid-free SAA in both blood and tissue as a consequence of acute and chronic inflammation; proteolytic processing of SAA to AA, which releases the carboxyterminal third of the molecule and which may involve internalization of SAA by macrophages, intracellular proteolysis, and release of amyloidogenic peptides into the extracellular space; and intrinsic fibrillogenic properties of the molecule (<a class="graphic graphic_figure graphicRef116202" href="/d/graphic/116202.html" rel="external">figure 1</a>). (See <a class="local">'Principal pathogenic factors'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Westermark GT, Fändrich M, Westermark P. AA amyloidosis: pathogenesis and targeted therapy. Annu Rev Pathol 2015; 10:321.</a></li><li><a class="nounderline abstract_t">Papa R, Lachmann HJ. Secondary, AA, Amyloidosis. Rheum Dis Clin North Am 2018; 44:585.</a></li><li><a class="nounderline abstract_t">Takase H, Tanaka M, Yamamoto A, et al. Structural requirements of glycosaminoglycans for facilitating amyloid fibril formation of human serum amyloid A. Amyloid 2016; 23:67.</a></li><li><a class="nounderline abstract_t">Ogawa M, Shintani-Domoto Y, Nagashima Y, et al. Mass spectrometry-based absolute quantification of amyloid proteins in pathology tissue specimens: Merits and limitations. PLoS One 2020; 15:e0235143.</a></li><li><a class="nounderline abstract_t">Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid 2020; 27:217.</a></li><li><a class="nounderline abstract_t">Sorić Hosman I, Kos I, Lamot L. Serum Amyloid A in Inflammatory Rheumatic Diseases: A Compendious Review of a Renowned Biomarker. Front Immunol 2020; 11:631299.</a></li><li><a class="nounderline abstract_t">Sack GH Jr. Serum Amyloid A (SAA) Proteins. Subcell Biochem 2020; 94:421.</a></li><li><a class="nounderline abstract_t">Frame NM, Gursky O. Structure of serum amyloid A suggests a mechanism for selective lipoprotein binding and functions: SAA as a hub in macromolecular interaction networks. FEBS Lett 2016; 590:866.</a></li><li><a class="nounderline abstract_t">Lu J, Yu Y, Zhu I, et al. Structural mechanism of serum amyloid A-mediated inflammatory amyloidosis. Proc Natl Acad Sci U S A 2014; 111:5189.</a></li><li><a class="nounderline abstract_t">Gallo G, Wisniewski T, Choi-Miura NH, et al. Potential role of apolipoprotein-E in fibrillogenesis. Am J Pathol 1994; 145:526.</a></li><li><a class="nounderline abstract_t">Kisilevsky R, Ancsin JB, Szarek WA, Petanceska S. Heparan sulfate as a therapeutic target in amyloidogenesis: prospects and possible complications. Amyloid 2007; 14:21.</a></li><li><a class="nounderline abstract_t">Husby G, Stenstad T, Magnus JH, et al. Interaction between circulating amyloid fibril protein precursors and extracellular tissue matrix components in the pathogenesis of systemic amyloidosis. Clin Immunol Immunopathol 1994; 70:2.</a></li><li><a class="nounderline abstract_t">Tennent GA, Lovat LB, Pepys MB. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A 1995; 92:4299.</a></li><li><a class="nounderline abstract_t">Pinney JH, Lachmann HJ. Systemic AA amyloidosis. Subcell Biochem 2012; 65:541.</a></li><li><a class="nounderline abstract_t">Kisilevsky R, Manley PN. Acute-phase serum amyloid A: perspectives on its physiological and pathological roles. Amyloid 2012; 19:5.</a></li><li><a class="nounderline abstract_t">O'Hara R, Murphy EP, Whitehead AS, et al. Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. Arthritis Rheum 2004; 50:1788.</a></li><li><a class="nounderline abstract_t">Wilson PG, Thompson JC, Shridas P, et al. Serum Amyloid A Is an Exchangeable Apolipoprotein. Arterioscler Thromb Vasc Biol 2018; 38:1890.</a></li><li><a class="nounderline abstract_t">Hu Z, Bang YJ, Ruhn KA, Hooper LV. Molecular basis for retinol binding by serum amyloid A during infection. Proc Natl Acad Sci U S A 2019; 116:19077.</a></li><li><a class="nounderline abstract_t">Thorn CF, Lu ZY, Whitehead AS. Regulation of the human acute phase serum amyloid A genes by tumour necrosis factor-alpha, interleukin-6 and glucocorticoids in hepatic and epithelial cell lines. Scand J Immunol 2004; 59:152.</a></li><li><a class="nounderline abstract_t">Ray A, Shakya A, Kumar D, et al. Inflammation-responsive transcription factor SAF-1 activity is linked to the development of amyloid A amyloidosis. J Immunol 2006; 177:2601.</a></li><li><a class="nounderline abstract_t">Sack GH Jr. Serum amyloid A - a review. Mol Med 2018; 24:46.</a></li><li><a class="nounderline abstract_t">Sun L, Ye RD. Serum amyloid A1: Structure, function and gene polymorphism. Gene 2016; 583:48.</a></li><li><a class="nounderline abstract_t">Sipe J. Revised nomenclature for serum amyloid A (SAA). Nomenclature Committee of the International Society of Amyloidosis. Part 2. Amyloid 1999; 6:67.</a></li><li><a class="nounderline abstract_t">Zhang Y, Zhang J, Sheng H, et al. Acute phase reactant serum amyloid A in inflammation and other diseases. Adv Clin Chem 2019; 90:25.</a></li><li><a class="nounderline abstract_t">Obici L, Raimondi S, Lavatelli F, et al. Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum 2009; 61:1435.</a></li><li><a class="nounderline abstract_t">van der Hilst JC, Yamada T, Op den Camp HJ, et al. Increased susceptibility of serum amyloid A 1.1 to degradation by MMP-1: potential explanation for higher risk of type AA amyloidosis. Rheumatology (Oxford) 2008; 47:1651.</a></li><li><a class="nounderline abstract_t">Migita K, Agematsu K, Masumoto J, et al. The contribution of SAA1 polymorphisms to Familial Mediterranean fever susceptibility in the Japanese population. PLoS One 2013; 8:e55227.</a></li><li><a class="nounderline abstract_t">Yashiro M, Furukawa H, Asano T, et al. Serum amyloid A1 (SAA1) gene polymorphisms in Japanese patients with adult-onset Still's disease. Medicine (Baltimore) 2018; 97:e13394.</a></li><li><a class="nounderline abstract_t">Atoyan S, Hayrapetyan H, Sarkisian T, Ben-Chetrit E. MEFV and SAA1 genotype associations with clinical features of familial Mediterranean fever and amyloidosis in Armenia. Clin Exp Rheumatol 2016; 34:72.</a></li><li><a class="nounderline abstract_t">van der Westhuyzen DR, de Beer FC, Webb NR. HDL cholesterol transport during inflammation. Curr Opin Lipidol 2007; 18:147.</a></li><li><a class="nounderline abstract_t">Poitou C, Divoux A, Faty A, et al. Role of serum amyloid a in adipocyte-macrophage cross talk and adipocyte cholesterol efflux. J Clin Endocrinol Metab 2009; 94:1810.</a></li><li><a class="nounderline abstract_t">Ancsin JB, Kisilevsky R. Characterization of high affinity binding between laminin and the acute-phase protein, serum amyloid A. J Biol Chem 1997; 272:406.</a></li><li><a class="nounderline abstract_t">Shah C, Hari-Dass R, Raynes JG. Serum amyloid A is an innate immune opsonin for Gram-negative bacteria. Blood 2006; 108:1751.</a></li><li><a class="nounderline abstract_t">Mullan RH, Bresnihan B, Golden-Mason L, et al. Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-kappaB-dependent signal transduction pathway. Arthritis Rheum 2006; 54:105.</a></li><li><a class="nounderline abstract_t">Lee HY, Kim SD, Shim JW, et al. LL-37 inhibits serum amyloid A-induced IL-8 production in human neutrophils. Exp Mol Med 2009; 41:325.</a></li><li><a class="nounderline abstract_t">He RL, Zhou J, Hanson CZ, et al. Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like receptor 2. Blood 2009; 113:429.</a></li><li><a class="nounderline abstract_t">Urieli-Shoval S, Shubinsky G, Linke RP, et al. Adhesion of human platelets to serum amyloid A. Blood 2002; 99:1224.</a></li><li><a class="nounderline abstract_t">Page MJ, Thomson GJA, Nunes JM, et al. Serum amyloid A binds to fibrin(ogen), promoting fibrin amyloid formation. Sci Rep 2019; 9:3102.</a></li><li><a class="nounderline abstract_t">Ye RD, Sun L. Emerging functions of serum amyloid A in inflammation. J Leukoc Biol 2015; 98:923.</a></li><li><a class="nounderline abstract_t">Webb NR. High-Density Lipoproteins and Serum Amyloid A (SAA). Curr Atheroscler Rep 2021; 23:7.</a></li><li><a class="nounderline abstract_t">Ancsin JB, Kisilevsky R. The heparin/heparan sulfate-binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis. J Biol Chem 1999; 274:7172.</a></li><li><a class="nounderline abstract_t">Vallon R, Freuler F, Desta-Tsedu N, et al. Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. J Immunol 2001; 166:2801.</a></li><li><a class="nounderline abstract_t">Migita K, Koga T, Torigoshi T, et al. Serum amyloid A protein stimulates CCL20 production in rheumatoid synoviocytes. Rheumatology (Oxford) 2009; 48:741.</a></li><li><a class="nounderline abstract_t">Connolly M, Mullan RH, McCormick J, et al. Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy. Arthritis Rheum 2012; 64:1035.</a></li><li><a class="nounderline abstract_t">Connolly M, Rooney PR, McGarry T, et al. Acute serum amyloid A is an endogenous TLR2 ligand that mediates inflammatory and angiogenic mechanisms. Ann Rheum Dis 2016; 75:1392.</a></li><li><a class="nounderline abstract_t">Migita K, Koga T, Komori A, et al. Influence of Janus kinase inhibition on interleukin 6-mediated induction of acute-phase serum amyloid A in rheumatoid synovium. J Rheumatol 2011; 38:2309.</a></li><li><a class="nounderline abstract_t">Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356:2361.</a></li><li><a class="nounderline abstract_t">Bunker D, Gorevic P. AA amyloidosis: Mount Sinai experience, 1997-2012. Mt Sinai J Med 2012; 79:749.</a></li><li><a class="nounderline abstract_t">Gruys E, Snel FW. Animal models for reactive amyloidosis. Baillieres Clin Rheumatol 1994; 8:599.</a></li><li><a class="nounderline abstract_t">Landman WJ. Amyloid arthropathy in chickens. Vet Q 1999; 21:78.</a></li><li><a class="nounderline abstract_t">Sevimli A, Misirlioğlu D, Yağci A, et al. The role of chicken IL-1beta, IL-6 and TNF-alpha in the occurrence of amyloid arthropathy. Vet Res Commun 2008; 32:499.</a></li><li><a class="nounderline abstract_t">Murakami T, Ishiguro N, Higuchi K. Transmission of systemic AA amyloidosis in animals. Vet Pathol 2014; 51:363.</a></li><li><a class="nounderline abstract_t">Grateau G. Musculoskeletal disorders in secondary amyloidosis and hereditary fevers. Best Pract Res Clin Rheumatol 2003; 17:929.</a></li><li><a class="nounderline abstract_t">van der Hilst JC. Recent insights into the pathogenesis of type AA amyloidosis. ScientificWorldJournal 2011; 11:641.</a></li><li><a class="nounderline abstract_t">Röcken C, Menard R, Bühling F, et al. Proteolysis of serum amyloid A and AA amyloid proteins by cysteine proteases: cathepsin B generates AA amyloid proteins and cathepsin L may prevent their formation. Ann Rheum Dis 2005; 64:808.</a></li><li><a class="nounderline abstract_t">Kinkley SM, Bagshaw WL, Tam SP, Kisilevsky R. The path of murine serum amyloid A through peritoneal macrophages. Amyloid 2006; 13:123.</a></li><li><a class="nounderline abstract_t">Patke S, Srinivasan S, Maheshwari R, et al. Characterization of the oligomerization and aggregation of human Serum Amyloid A. PLoS One 2013; 8:e64974.</a></li><li><a class="nounderline abstract_t">Jayaraman S, Gantz DL, Haupt C, Gursky O. Serum amyloid A forms stable oligomers that disrupt vesicles at lysosomal pH and contribute to the pathogenesis of reactive amyloidosis. Proc Natl Acad Sci U S A 2017; 114:E6507.</a></li><li><a class="nounderline abstract_t">Westermark GT, Engström U, Westermark P. The N-terminal segment of protein AA determines its fibrillogenic property. Biochem Biophys Res Commun 1992; 182:27.</a></li><li><a class="nounderline abstract_t">Yamada T, Kluve-Beckerman B, Liepnieks JJ, Benson MD. Fibril formation from recombinant human serum amyloid A. Biochim Biophys Acta 1994; 1226:323.</a></li><li><a class="nounderline abstract_t">Ray A, Schatten H, Ray BK. Activation of Sp1 and its functional co-operation with serum amyloid A-activating sequence binding factor in synoviocyte cells trigger synergistic action of interleukin-1 and interleukin-6 in serum amyloid A gene expression. J Biol Chem 1999; 274:4300.</a></li><li><a class="nounderline abstract_t">Lee HY, Kim MK, Park KS, et al. Serum amyloid A stimulates matrix-metalloproteinase-9 upregulation via formyl peptide receptor like-1-mediated signaling in human monocytic cells. Biochem Biophys Res Commun 2005; 330:989.</a></li><li><a class="nounderline abstract_t">Sjöholm K, Palming J, Olofsson LE, et al. A microarray search for genes predominantly expressed in human omental adipocytes: adipose tissue as a major production site of serum amyloid A. J Clin Endocrinol Metab 2005; 90:2233.</a></li><li><a class="nounderline abstract_t">Jahangiri A, Wilson PG, Hou T, et al. Serum amyloid A is found on ApoB-containing lipoproteins in obese humans with diabetes. Obesity (Silver Spring) 2013; 21:993.</a></li><li><a class="nounderline abstract_t">Beridze Vaktangova N, García Moreira V, García Castañón S, et al. AA amyloidosis associated with morbid obesity (clinical case). Reumatol Clin (Engl Ed) 2020; 16:493.</a></li><li><a class="nounderline abstract_t">Eckhardt ER, Witta J, Zhong J, et al. Intestinal epithelial serum amyloid A modulates bacterial growth in vitro and pro-inflammatory responses in mouse experimental colitis. BMC Gastroenterol 2010; 10:133.</a></li><li><a class="nounderline abstract_t">Sano T, Huang W, Hall JA, et al. An IL-23R/IL-22 Circuit Regulates Epithelial Serum Amyloid A to Promote Local Effector Th17 Responses. Cell 2015; 163:381.</a></li><li><a class="nounderline abstract_t">Murdoch CC, Espenschied ST, Matty MA, et al. Intestinal Serum amyloid A suppresses systemic neutrophil activation and bactericidal activity in response to microbiota colonization. PLoS Pathog 2019; 15:e1007381.</a></li><li><a class="nounderline abstract_t">Lee JY, Hall JA, Kroehling L, et al. Serum Amyloid A Proteins Induce Pathogenic Th17 Cells and Promote Inflammatory Disease. Cell 2020; 183:2036.</a></li><li><a class="nounderline abstract_t">Shridas P, De Beer MC, Webb NR. High-density lipoprotein inhibits serum amyloid A-mediated reactive oxygen species generation and NLRP3 inflammasome activation. J Biol Chem 2018; 293:13257.</a></li><li><a class="nounderline abstract_t">Gillmore JD, Lovat LB, Persey MR, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001; 358:24.</a></li><li><a class="nounderline abstract_t">Gertz MA, Skinner M, Sipe JD, et al. Serum amyloid A protein and C-reactive protein in systemic amyloidosis. Clin Exp Rheumatol 1985; 3:317.</a></li><li><a class="nounderline abstract_t">De Beer FC, Mallya RK, Fagan EA, et al. Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet 1982; 2:231.</a></li><li><a class="nounderline abstract_t">Ajiro J, Narita I, Sato F, et al. SAA1 gene polymorphisms and the risk of AA amyloidosis in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2006; 16:294.</a></li><li><a class="nounderline abstract_t">Utku U, Dilek M, Akpolat I, et al. SAA1 alpha/alpha alleles in Behçet's disease related amyloidosis. Clin Rheumatol 2007; 26:927.</a></li><li class="breakAll">Ombrello AK, Aksentijevich I. AA amyloidosis. In: Amyloid and Related Disorders: Surgical Pathology and Clinical Correlations, Pickens MM (Ed), Springer, 2012. p.31.</li><li><a class="nounderline abstract_t">Kluve-Beckerman B, Liepnieks JJ, Wang L, Benson MD. A cell culture system for the study of amyloid pathogenesis. Amyloid formation by peritoneal macrophages cultured with recombinant serum amyloid A. Am J Pathol 1999; 155:123.</a></li><li><a class="nounderline abstract_t">Migita K, Eguchi K, Tsukada T, et al. Increased circulating serum amyloid A protein derivatives in rheumatoid arthritis patients with secondary amyloidosis. Lab Invest 1996; 75:371.</a></li><li><a class="nounderline abstract_t">Westermark GT, Westermark P, Sletten K. Amyloid fibril protein AA. Characterization of uncommon subspecies from a patient with rheumatoid arthritis. Lab Invest 1987; 57:57.</a></li><li><a class="nounderline abstract_t">Westermark GT, Sletten K, Westermark P. Massive vascular AA-amyloidosis: a histologically and biochemically distinctive subtype of reactive systemic amyloidosis. Scand J Immunol 1989; 30:605.</a></li><li><a class="nounderline abstract_t">Bansal A, Schmidt M, Rennegarbe M, et al. AA amyloid fibrils from diseased tissue are structurally different from in vitro formed SAA fibrils. Nat Commun 2021; 12:1013.</a></li><li><a class="nounderline abstract_t">Senthilkumar S, Chang E, Jayakumar R. Diffusible amyloid oligomers trigger systemic amyloidosis in mice. Biochem J 2008; 415:207.</a></li><li><a class="nounderline abstract_t">Westermark GT, Westermark P. Serum amyloid A and protein AA: molecular mechanisms of a transmissible amyloidosis. FEBS Lett 2009; 583:2685.</a></li><li><a class="nounderline abstract_t">Gorevic PD. Amyloid and inflammation. Proc Natl Acad Sci U S A 2013; 110:16291.</a></li></ol></div><div id="topicVersionRevision">Topic 5619 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25387054" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : AA amyloidosis: pathogenesis and targeted therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30274625" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Secondary, AA, Amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27097047" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Structural requirements of glycosaminoglycans for facilitating amyloid fibril formation of human serum amyloid A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32609750" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mass spectrometry-based absolute quantification of amyloid proteins in pathology tissue specimens: Merits and limitations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33100054" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33679725" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Serum Amyloid A in Inflammatory Rheumatic Diseases: A Compendious Review of a Renowned Biomarker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32189310" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Serum Amyloid A (SAA) Proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26918388" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Structure of serum amyloid A suggests a mechanism for selective lipoprotein binding and functions: SAA as a hub in macromolecular interaction networks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24706838" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Structural mechanism of serum amyloid A-mediated inflammatory amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8080036" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Potential role of apolipoprotein-E in fibrillogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17453622" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Heparan sulfate as a therapeutic target in amyloidogenesis: prospects and possible complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8261664" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Interaction between circulating amyloid fibril protein precursors and extracellular tissue matrix components in the pathogenesis of systemic amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7753801" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23225016" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Systemic AA amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22320226" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Acute-phase serum amyloid A: perspectives on its physiological and pathological roles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15188355" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29976766" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Serum Amyloid A Is an Exchangeable Apolipoprotein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31484771" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Molecular basis for retinol binding by serum amyloid A during infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14871291" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Regulation of the human acute phase serum amyloid A genes by tumour necrosis factor-alpha, interleukin-6 and glucocorticoids in hepatic and epithelial cell lines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16888022" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Inflammation-responsive transcription factor SAF-1 activity is linked to the development of amyloid A amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30165816" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Serum amyloid A - a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26945629" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Serum amyloid A1: Structure, function and gene polymorphism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10211414" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Revised nomenclature for serum amyloid A (SAA). Nomenclature Committee of the International Society of Amyloidosis. Part 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31122611" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Acute phase reactant serum amyloid A in inflammation and other diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19790131" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18815155" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Increased susceptibility of serum amyloid A 1.1 to degradation by MMP-1: potential explanation for higher risk of type AA amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23437051" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The contribution of SAA1 polymorphisms to Familial Mediterranean fever susceptibility in the Japanese population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30544414" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Serum amyloid A1 (SAA1) gene polymorphisms in Japanese patients with adult-onset Still's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27791951" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : MEFV and SAA1 genotype associations with clinical features of familial Mediterranean fever and amyloidosis in Armenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17353662" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : HDL cholesterol transport during inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19223523" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Role of serum amyloid a in adipocyte-macrophage cross talk and adipocyte cholesterol efflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8995276" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Characterization of high affinity binding between laminin and the acute-phase protein, serum amyloid A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16735604" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Serum amyloid A is an innate immune opsonin for Gram-negative bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16385502" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-kappaB-dependent signal transduction pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19307752" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : LL-37 inhibits serum amyloid A-induced IL-8 production in human neutrophils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18952897" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like receptor 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11830469" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Adhesion of human platelets to serum amyloid A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30816210" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Serum amyloid A binds to fibrin(ogen), promoting fibrin amyloid formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26130702" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Emerging functions of serum amyloid A in inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33447953" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : High-Density Lipoproteins and Serum Amyloid A (SAA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10066777" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The heparin/heparan sulfate-binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11160347" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19447772" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Serum amyloid A protein stimulates CCL20 production in rheumatoid synoviocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22076945" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Acute-phase serum amyloid A regulates tumor necrosis factorαand matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26290589" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Acute serum amyloid A is an endogenous TLR2 ligand that mediates inflammatory and angiogenic mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21844139" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Influence of Janus kinase inhibition on interleukin 6-mediated induction of acute-phase serum amyloid A in rheumatoid synovium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17554117" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Natural history and outcome in systemic AA amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23239212" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : AA amyloidosis: Mount Sinai experience, 1997-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7954864" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Animal models for reactive amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10427631" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Amyloid arthropathy in chickens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18612836" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The role of chicken IL-1beta, IL-6 and TNF-alpha in the occurrence of amyloid arthropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24280941" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Transmission of systemic AA amyloidosis in animals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15123044" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Musculoskeletal disorders in secondary amyloidosis and hereditary fevers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21403980" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Recent insights into the pathogenesis of type AA amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15897303" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Proteolysis of serum amyloid A and AA amyloid proteins by cysteine proteases: cathepsin B generates AA amyloid proteins and cathepsin L may prevent their formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17062378" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The path of murine serum amyloid A through peritoneal macrophages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23750222" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Characterization of the oligomerization and aggregation of human Serum Amyloid A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28743750" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Serum amyloid A forms stable oligomers that disrupt vesicles at lysosomal pH and contribute to the pathogenesis of reactive amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1731787" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The N-terminal segment of protein AA determines its fibrillogenic property.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8054364" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Fibril formation from recombinant human serum amyloid A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9933631" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Activation of Sp1 and its functional co-operation with serum amyloid A-activating sequence binding factor in synoviocyte cells trigger synergistic action of interleukin-1 and interleukin-6 in serum amyloid A gene expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15809093" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Serum amyloid A stimulates matrix-metalloproteinase-9 upregulation via formyl peptide receptor like-1-mediated signaling in human monocytic cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15623807" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A microarray search for genes predominantly expressed in human omental adipocytes: adipose tissue as a major production site of serum amyloid A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23784902" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Serum amyloid A is found on ApoB-containing lipoproteins in obese humans with diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30527964" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : AA amyloidosis associated with morbid obesity (clinical case).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21067563" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Intestinal epithelial serum amyloid A modulates bacterial growth in vitro and pro-inflammatory responses in mouse experimental colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26411290" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : An IL-23R/IL-22 Circuit Regulates Epithelial Serum Amyloid A to Promote Local Effector Th17 Responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30845179" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Intestinal Serum amyloid A suppresses systemic neutrophil activation and bactericidal activity in response to microbiota colonization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33357400" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Serum Amyloid A Proteins Induce Pathogenic Th17 Cells and Promote Inflammatory Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29976759" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : High-density lipoprotein inhibits serum amyloid A-mediated reactive oxygen species generation and NLRP3 inflammasome activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11454373" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4085162" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Serum amyloid A protein and C-reactive protein in systemic amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6124669" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17039310" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : SAA1 gene polymorphisms and the risk of AA amyloidosis in Japanese patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17039260" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : SAA1 alpha/alpha alleles in Behçet's disease related amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17039260" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : SAA1 alpha/alpha alleles in Behçet's disease related amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10393845" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A cell culture system for the study of amyloid pathogenesis. Amyloid formation by peritoneal macrophages cultured with recombinant serum amyloid A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8804360" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Increased circulating serum amyloid A protein derivatives in rheumatoid arthritis patients with secondary amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3298850" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Amyloid fibril protein AA. Characterization of uncommon subspecies from a patient with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2587936" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Massive vascular AA-amyloidosis: a histologically and biochemically distinctive subtype of reactive systemic amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33579941" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : AA amyloid fibrils from diseased tissue are structurally different from in vitro formed SAA fibrils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18564059" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Diffusible amyloid oligomers trigger systemic amyloidosis in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19393650" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Serum amyloid A and protein AA: molecular mechanisms of a transmissible amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24067661" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Amyloid and inflammation.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
